pharmaphorum November 9, 2025
Phil Taylor

The Trump administration has released details of a most-favoured nation (MFN) drug pricing programme for medicines provided by Medicaid, the federal health insurance programme for people with low incomes and the disabled.

The Centers for Medicare & Medicaid Services (CMS) is calling its pilot scheme the GENErating cost Reductions fOr US Medicaid or GENEROUS model, and is now seeking companies that wish to take part.

The premise is similar to the MFN system Trump is trying to implement for Medicare – with deals already announced with Pfizer, AstraZeneca, and Merck KGaA – and will tie the prices of medicines provided by Medicaid in the US to the lowest prices charged for them in eight other countries, specifically the UK, France,...

Today's Sponsors

Venturous
ZeOmega

Today's Sponsor

Venturous

Continue Reading

 
Topics: CMS, Congress / White House, Govt Agencies, Insurance, Medicaid
Related Articles:
Reengineering ACOs To Make Medicare Competitive
Major CMS‑Recognized Hospital Types
No Surprises disputes increasing even as arbiters catch up, CMS says
CMS proposes nearly flat Medicare Advantage payments for 2027: 6 notes
The Persistent Rising Tide of U.S. Health Care Spending

Share Article